Search Result

Results for "

glucose levels

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GLUT (3) SGLT (2) Acyltransferase (1) Adrenergic Receptor (2) Akt (6) Aldose Reductase (1) AMPK (4) Amylases (1) Amylin Receptor (2) Antibiotic (3) Apoptosis (5) Autophagy (5) Bacterial (4) Beclin1 (3) Biochemical Assay Reagents (2) Caspase (4) Dipeptidyl Peptidase (1) Endogenous Metabolite (4) ERK (1) FABP (1) FBPase (1) FOXO (1) Free Fatty Acid Receptor (5) G protein-coupled Bile Acid Receptor 1 (1) GCGR (1) GLP Receptor (3) Glucokinase (3) Glucosidase (7) GPR119 (2) HIF/HIF Prolyl-Hydroxylase (3) Influenza Virus (1) Insulin Receptor (6) JNK (3) MDM-2/p53 (1) Melatonin Receptor (1) Microtubule/Tubulin (1) MMP (3) NF-κB (3) p38 MAPK (2) PEPCK (1) Phosphatase (3) Potassium Channel (1) PPAR (9) Reactive Oxygen Species (2) Small Interfering RNA (siRNA) (2) TNF Receptor (1) VEGFR (3)
By Research Areas:	Cancer (9) Cardiovascular Disease (3) Endocrinology (7) Infection (4) Inflammation/Immunology (7) Metabolic Disease (75) Neurological Disease (2)
Oligonucleotides:	siRNAs (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: GLUT SGLT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-110173

TC-G 1005	G protein-coupled Bile Acid Receptor 1	Metabolic Disease
TC-G 1005 is a potent, selective and orally active agonist of the BA receptor Takeda G protein-coupled receptor 5 (TGR5), with EC₅₀s of 0.72 and 6.2 nM for hTGR5 and mTGR5, respectively. TC-G 1005 can reduce glucose levels in vivo .

HY-N1503

Methyl deacetylasperulosidate 6α-Hydroxygeniposide; Deacetylasperulosidic acid methyl ester	Others	Metabolic Disease
Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-122083

T2384	PPAR	Metabolic Disease
T2384 is a peroxisome proliferator-activated receptor γ (PPARγ) ligand. T2384 also is an orally active antidiabetic agent. T2384 reduces the fasting plasma glucose levels and plasma insulin levels .

HY-123171

ASP8497	Others	Metabolic Disease
ASP8497 is a competitive dipeptidyl peptidase IV (DPP-IV) inhibitor that reduces blood glucose levels and increases plasma active GLP-1 and insulin levels without causing hypoglycemia in fasted normal mice. ASP8497 can be utilized for antihyperglycemic research .

HY-158820

Cosdosiran QPI-1007	Small Interfering RNA (siRNA) Caspase	Cardiovascular Disease
Cosdosiran is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.?

HY-158820A

Cosdosiran sodium QPI-1007 sodium	Small Interfering RNA (siRNA) Caspase	Cardiovascular Disease
Cosdosiran sodium is a chemically modified siRNA designed to temporarily inhibit expression of the caspase 2 protein and can be used for the study of nonarteritic anterior ischemic optic neuropathy and other optic neuropathies such as glaucoma that result in the death of retinal ganglion cells.?

HY-E70364

IgdE protease	Biochemical Assay Reagents	Inflammation/Immunology
IgdE protease is a cysteine protease, which is initially isolated from Streptococcus agalactiae. IgdE protease digests monoclonal antibodies (mAbs) of the IgG1 type specifically at their upper hinge region, produces Fc/2, hinge peptide dimers, and Fab fragment. IgdE protease can be used in disulfide bonds and free thiol analysis, as it requires no reducing agents for cleavage .

HY-117446

AS-1669058	GPR119	Metabolic Disease
AS-1669058 is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 induces insulin secretion in response to high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 improved glucose tolerance and reduced blood glucose levels in db/db mice .

HY-14747

Piragliatin RO4389620	Glucokinase	Metabolic Disease
Piragliatin (RO4389620) is an activator for glucokinase, which reduces endogenous glucose production, increases β-cell function and glucose utilization, and thus decreases the blood glucose levels. Piragliatin exhibits antidiabetic efficacy .

HY-117446A

AS-1669058 free base	GPR119	Metabolic Disease
AS-1669058 free base is a GPR119 agonist and a potential inhibitor of type 2 diabetes. AS-1669058 free base induces insulin secretion induced by high blood glucose levels in vitro and in vivo and increases insulin promoter activity. In animal studies, AS-1669058 free base improved glucose tolerance and reduced blood glucose levels in db/db mice.

HY-W010031

1-Methyluric acid	Endogenous Metabolite	Metabolic Disease
1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.

HY-P0035

Insulin (human) Maximum Cited Publications 42 Publications Verification	Insulin Receptor	Metabolic Disease Endocrinology
Insulin (human) is a polypeptide hormone that regulates the level of glucose. Insulin (human) can be used for the diabetes mellitus .

HY-P0035A

Insulin solution (human) Maximum Cited Publications 42 Publications Verification	Insulin Receptor	Metabolic Disease
Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus .

HY-122613

YM543 free base	SGLT	Metabolic Disease
YM543 free base is a potent and orally active *sodium-glucose* cotransporter (SGLT) 2** inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .

HY-N8196

Isorhamnetin 3,7-di-O-β-D-glucopyranoside Isorhamnetin-3,7-diglucoside; Isorhamnetin diglucoside	Others	Metabolic Disease
Isorhamnetin 3,7-di-O-β-D-glucopyranoside, a major flavonoid compound, is metabolized in vivo by intestinal bacteria to isorhamnetin and that isorhamnetin plays an important role as an antioxidant .

HY-N1427

Glycodeoxycholate Sodium Sodium glycyldeoxycholate	Endogenous Metabolite	Metabolic Disease
Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .

HY-156276

SP4e	PPAR	Metabolic Disease
SP4e is an activator of PPAR-γ, with the EC₅₀ of 739 nM in HK-2 cells. SP4e reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .

HY-156277

SP4f	PPAR	Metabolic Disease
SP4f is an activator ofPPAR-γ, with the EC₅₀ of 826 nM in HK-2 cells. SP4f reduces the blood glucose levels and lipid peroxidation, and increases glutathione levels and catalase activityin the Swiss albino mice .

HY-U00340

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-116930

S-20928	Melatonin Receptor	Metabolic Disease
S-20928 is an antagonist for melatonin receptor through inhibition of binding of melatonin to its receptors. S-20928 enhances the 2-Deoxy-D-glucose (2DG) (HY-13966)-induced increase in blood glucose and glucagon levels in rats brain .

HY-12219B

MSI-1701	Others	Metabolic Disease
MSI-1701 is an analogue of MSI-1436 which can control weight gain and blood glucose level extracted from patent US 7410959 B1.

HY-N3960

Glycyrin	PPAR Bacterial	Infection Metabolic Disease
Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .

HY-N3720

Demethoxycapillarisin 6-Demethoxycapillarisin	PEPCK	Metabolic Disease
Demethoxycapillarisin (6-Demethoxycapillarisin) inhibits PEPCK mRNA levels (IC₅₀: 43 μM) by activation of the PI3K pathway. Demethoxycapillarisin decreases glucose production .

HY-P1393

AC 187	Amylin Receptor	Endocrinology
AC 187 is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects .

HY-P1393A

AC 187 TFA	Amylin Receptor	Endocrinology
AC 187 TFA is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 TFA shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 TFA has neuroprotective effects .

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active *sodium glucose* cotransporter (SGLT2)** inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .

HY-101637

Reglitazar JT 501	PPAR	Metabolic Disease
Reglitazar is an agonist for peroxisome proliferator-activated receptor α and β (PPAR α and PPAR β), which enhances insulin sensitivity, lowers blood glucose and regulates blood lipid levels .

HY-117755

PF-739	AMPK	Metabolic Disease
PF-739 is an orally active and non-selective activator of AMPK. PF-739 activates 12 heterotrimeric AMPK complexes and significantly reduces the level of glucose in plasma complexes .

HY-162042

AMPK activator 14	AMPK	Metabolic Disease
AMPK activator 14 (compound 32) is an orally active AMPK activator. AMPK activator 14 decreases fasted glucose and insulin levels in a db/db mouse model of Type II diabetes .

HY-W709961

5-OAHSA 1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate	Endogenous Metabolite	Metabolic Disease Inflammation/Immunology
5-OAHSA (1-(3-Carboxypropyl)tetradecyl (9Z)-9-octadecenoate) is a endogenous lipid. 5-OAHSA reduces the level of blood glucose, improves the glucose tolerance, and stimulates the the secretion of GLP-1 and insulin. 5-OAHSA exhibits potential in regulating metabolic and inflammatory responses .

HY-144289

BMS-820132	Glucokinase	Metabolic Disease
BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC₅₀ of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .

HY-N12353

Stevisalioside A	Phosphatase	Metabolic Disease
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-N1503R

Methyl deacetylasperulosidate (Standard)	Others	Metabolic Disease
Methyl deacetylasperulosidate (Standard) is the analytical standard of Methyl deacetylasperulosidate. This product is intended for research and analytical applications. Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-N4195

Resveratroloside 1 Publications Verification Resveratrol glycoside; trans-Resveratrol 4'-O-β-D-glucopyranoside	Glucosidase	Cardiovascular Disease Metabolic Disease
Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC₅₀ of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect .

HY-122120

Rafabegron AJ‐9677	Adrenergic Receptor	Metabolic Disease
Rafabegron (AJ-9677) is a specific beta3-adrenoceptor agonist. Rafabegron can reduce blood glucose, insulin, FFA, and triglyceride levels in diabetic and obese mouse models .

HY-131334

AMPK activator 4	AMPK	Metabolic Disease
AMPK activator 4 is a potent AMPK activator without inhibition of mitochondrial complex I. AMPK activator 4 selectively activates AMPK in the muscle tissues. AMPK activator 4 dose-dependently improves glucose tolerance in normal mice, and significantly lowers fasting blood glucose level and ameliorates insulin resistance in db/db diabetic mice. Anti-hyperglycemic effect .

HY-155961

Antidiabetic agent 2	Dipeptidyl Peptidase Phosphatase Amylases Glucosidase	Metabolic Disease
Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC₅₀s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels .

HY-161892

FABP4-IN-4	FABP	Metabolic Disease Inflammation/Immunology
FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC₅₀ of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .

HY-148684

AMPK activator 10	AMPK	Metabolic Disease
AMPK activator 10 is an orally active, potent AMPK activator with EC₁₅₀ of 44.3 nM by cell-ELISA. AMPK activator 10 increases the phosphorylation levels of ACC. AMPK activator 10 exhibits a glucose lowering effect .

HY-N11551

Salvifaricin	Others	Others Metabolic Disease
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-N0936

Coixol 1 Publications Verification 6-Methoxy-2-benzoxazolinone; 6-MBOA	Others	Inflammation/Immunology
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .

HY-117172

CP320626	Others	Metabolic Disease
CP320626 is a potent inhibitor of human liver glycogen phosphorylase (IC₅₀=205 nM). CP320626 reduces blood glucose in diabetic mice without changing plasma insulin levels. CP320626 can be used in the study of type 2 diabetes .

HY-W145497

D-(+)-Sorbose	Insulin Receptor	Metabolic Disease
D-(+)-Sorbose, an active enantiomer of D-Sorbose, which inhibits disaccharidase activity and demonstrates suppressive action on postprandial blood levels of glucose and insulin in the rat. D-sorbose acts as a sweetener may contribute to the prevention of lifestyle-related diseases, such as type 2 diabetes mellitus .

HY-148529

Midaglizole (±)-DG5128 free base; DG5128 free base	Adrenergic Receptor	Metabolic Disease
Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo .

HY-135505

JTP-103237	Acyltransferase	Metabolic Disease
JTP-103237 is a MGAT2 inhibitor (IC₅₀: 0.019 μM and 6.423 μM for hMGAT2 and hMGAT3 respectively). JTP-103237 modulates fat absorption, decreases plasma glucose levels and prevents diet-induced obesity .

HY-12614

AMG-1694	Glucokinase	Metabolic Disease
AMG-1694 is a potent glucokinase–glucokinase regulatory protein (GK-GKRP) disruptors and promotes the dissociation of the GK-GKRP complex with an IC₅₀ of 7 nM, indirectly increasing GK enzymatic activity. AMG-1694 potently reverses the inhibitory effect of GKRP on GK activity and promotes GK translocation. AMG-1694 normalizes blood glucose levels in several rodent models of diabetes and lowes blood glucose restricted to diabetic and not normoglycaemic animals .

HY-149409

α-Glucosidase-IN-31	Glucosidase	Metabolic Disease
α-Glucosidase-IN-31 (compound R1) is an orally active, potent α-Glucosidase inhibitor with an IC₅₀ value of 10.1 μM. α-Glucosidase-IN-31 significantly reduces the blood glucose level and has antidiabetic activity .

HY-151138

α-Glucosidase-IN-16	Glucosidase	Metabolic Disease
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC₅₀ value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .

HY-B1245

Salsalate 2 Publications Verification Salicylsalicylic acid; Disalicylic acid	Reactive Oxygen Species	Inflammation/Immunology
Salsalate, a non-acetylated salicylate, is an effective antirheumatic agent that bypasses gastric absorption and also avoids cyclooxygenase inhibition. Salsalate has anti-inflammatory activity and reduces glucose levels, insulin resistance, and cytokine expression. Salsalate can be used in the research of type 2 diabetes .

Cat. No.	Product Name

HY-L045

Oxygen Sensing Compound Library

2,707 compounds

Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression.

Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival.

HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O₂ concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation.

MCE offers a unique collection of 2,707 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Cat. No.	Product Name	Target	Research Area

HY-137874

L-Glutamic γ-monohydroxamate	Peptides	Metabolic Disease Cancer
L-Glutamic γ-monohydroxamate is an antitumor agent, inhibits cell proliferation. L-Glutamic γ-monohydroxamate selectively inhibits the uptake of L-histidine into microvascular endothelial cell. L-Glutamic γ-monohydroxamate, as a vanadium ligand, activates glucose uptake and metabolism, thus decreases the blood glucose levels in vivo .

HY-P0035

Insulin (human) Maximum Cited Publications 42 Publications Verification	Insulin Receptor	Metabolic Disease Endocrinology
Insulin (human) is a polypeptide hormone that regulates the level of glucose. Insulin (human) can be used for the diabetes mellitus .

HY-P0035A

Insulin solution (human) Maximum Cited Publications 42 Publications Verification	Insulin Receptor	Metabolic Disease
Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus .

HY-P1393A

AC 187 TFA	Amylin Receptor	Endocrinology
AC 187 TFA is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 TFA shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 TFA has neuroprotective effects .

HY-P0034A

Ac-DEVD-CMK TFA 2 Publications Verification Caspase-3 Inhibitor III TFA	Caspase Apoptosis	Metabolic Disease
Ac-DEVD-CMK (Caspase-3 Inhibitor III) TFA is a selective and irreversible caspase-3 inhibitor. Ac-DEVD-CMK TFA significantly inhibits apoptosis induced by high levels of glucose or 3,20-dibenzoate (IDB; HY-137295). Ac-DEVD-CMK TFA can be used in a variety of experimental approaches to inhibit apoptosis .

HY-109556

Insulin Detemir	Akt ERK	Metabolic Disease
Insulin Detemir is an artificial insulin, shows effect on controlling blood sugar levels. Insulin Detemir stimulates GLP-1 secretion as a consequence of enhanced Gcg expression by a mechanism involving activation of Akt- and/or extracellular signal-regulated kinase (ERK)-dependent-cat and CREB signaling pathways. Insulin Detemir can be used for type 2 diabetes research .

HY-P10337

OXM-7	GCGR GLP Receptor	Metabolic Disease Endocrinology
OXM-7 is a dual agonist of GLP-1R (EC₅₀=0.024 nM) and GCGR (EC₅₀=0.082 nM). OXM-7 can enhance glucose-stimulated insulin secretion and hepatic glucose output. OXM-7 lowers blood glucose levels. OXM-7 improves lipid metabolism .

HY-P1393

AC 187	Amylin Receptor	Endocrinology
AC 187 is a potent and orally active amylin receptor antagonist with an IC₅₀ of 0.48 nM and a K_i of 0.275 nM. AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors. AC 187 has neuroprotective effects .

HY-P0034

Ac-DEVD-CMK Caspase-3 Inhibitor III	Caspase Apoptosis	Metabolic Disease
Ac-DEVD-CMK (Caspase-3 Inhibitor III) is a selective and irreversible caspase-3 inhibitor. Ac-DEVD-CMK significantly inhibits apoptosis induced by high levels of glucose or 3,20-dibenzoate (IDB; HY-137295). Ac-DEVD-CMK can be used in a variety of experimental approaches to inhibit apoptosis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1503

Methyl deacetylasperulosidate 6α-Hydroxygeniposide; Deacetylasperulosidic acid methyl ester	Structural Classification Iridoids Classification of Application Fields Terpenoids Source classification Rubiaceae Metabolic Disease Plants Disease Research Fields Hedyotis diffusa Willd.	Others
Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-W010031

1-Methyluric acid	Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Other disease Source classification Disease markers Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite
1-Methyluric acid acts on the urinary bladder mucosa and increases the blood glucose, insulin, triglyceride, and cholesterol levels.

HY-N1427

Glycodeoxycholate Sodium Sodium glycyldeoxycholate	Structural Classification Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields Steroids	Endogenous Metabolite
Glycodeoxycholate Sodium (Sodium glycyldeoxycholate) is a bile salt. Glycodeoxycholate Sodium has cytotoxicity to cancer cell, changes the permeability of the pancreatic duct and decreases glucose levels .

HY-N4195

Resveratroloside 1 Publications Verification Resveratrol glycoside; trans-Resveratrol 4'-O-β-D-glucopyranoside	Cardiovascular Disease Structural Classification Stilbenes Classification of Application Fields Polygonaceae Source classification Reynoutria japonica Houtt. Phenols Polyphenols Plants Disease Research Fields	Glucosidase
Resveratroloside (Resveratrol glycoside) is a competitive inhibitior of α-glucosidase with an IC₅₀ of 22.9 μM. Resveratroloside has the ability to regulate PBG (postprandial blood glucose) levels. Resveratroloside exhibits cardioprotective effect .

HY-N8196

Isorhamnetin 3,7-di-O-β-D-glucopyranoside Isorhamnetin-3,7-diglucoside; Isorhamnetin diglucoside	Flavonols Flavonoids Classification of Application Fields Brassica oleracea L. Source classification Phenols Polyphenols Metabolic Disease Plants Brassicaceae Disease Research Fields	Others
Isorhamnetin 3,7-di-O-β-D-glucopyranoside, a major flavonoid compound, is metabolized in vivo by intestinal bacteria to isorhamnetin and that isorhamnetin plays an important role as an antioxidant .

HY-N3960

Glycyrin	Structural Classification Leguminosae Source classification Coumarins Phenylpropanoids Plants Glycyrrhiza uralensis Fisch.	PPAR Bacterial
Glycyrin is a PPAR-γ ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .

HY-N3720

Demethoxycapillarisin 6-Demethoxycapillarisin	Source classification Artemisia dracunculus L. Plants Compositae	PEPCK
Demethoxycapillarisin (6-Demethoxycapillarisin) inhibits PEPCK mRNA levels (IC₅₀: 43 μM) by activation of the PI3K pathway. Demethoxycapillarisin decreases glucose production .

HY-N12353

Stevisalioside A	Structural Classification Isodon hispidus (Bentham) Murata Polysaccharides Source classification Plants Compositae Saccharides	Phosphatase
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC₅₀: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .

HY-N1503R

Methyl deacetylasperulosidate (Standard)	Structural Classification Iridoids Terpenoids Source classification Rubiaceae Plants Hedyotis diffusa Willd.	Others
Methyl deacetylasperulosidate (Standard) is the analytical standard of Methyl deacetylasperulosidate. This product is intended for research and analytical applications. Methyl deacetylasperulosidate is an iridoid and shows purgative effects in mice and lowers the blood glucose level in normal mice .

HY-N11551

Salvifaricin	Artemisia frigida Willd. Structural Classification Terpenoids Labiatae Source classification Diterpenoids Plants	Others
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .

HY-N0936

Coixol 1 Publications Verification 6-Methoxy-2-benzoxazolinone; 6-MBOA	Infection Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Gramineae Coix lacryma-jobi Linn. Plants Disease Research Fields	Others
Coixol (6-Methoxy-2-benzoxazolinone; 6-MBOA) is a potent and orally active anti-inflammatory agent. Coixol decreases the iNOS protein expression. Coixol inhibits the production of TNF-α, IL-6, and IL-1β. Coixol improves glucose tolerance and plasma insulin. Coixol decreases the blood glucose level .

HY-N10760

2a,3a,23-Trihydroxyurs-12,20(30)-dien-28-oic acid	Triterpenes Structural Classification Juglandaceae Terpenoids Source classification Cyclocarya paliurus (Batal.) Iljinsk. Plants	Others
2a,3a,23-Trihydroxyurs-12,20(30)-dien-28-oic acid (compound 3), a triterpenoid, significantly decreases the level of fibronectin in High-Glucose and TGF-b1 induced HK-2 cells with 27.66 % inhibition rate at 10 μM .

HY-B0239

Chloramphenicol Maximum Cited Publications 7 Publications Verification	Structural Classification Classification of Application Fields Anti-aging Source classification Antibacterial Disease Research Endogenous metabolite Other Antibiotics Infection Human Gut Microbiota Metabolites Plant Cell Culture Microorganisms Antibiotics Resistance Selection Animal Husbandry Anticancer Disease Research Fields Cancer	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N3021

D-chiro-Inositol	Structural Classification Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Endogenous Metabolite NF-κB TNF Receptor FOXO Microtubule/Tubulin
D-chiro-Inositol is a stereoisomer of inositol that exhibits activities such as improving glucose metabolism, anti-tumor effects, anti-inflammatory properties, and antioxidant activity. D-chiro-Inositol effectively alleviates cholestasis by enhancing bile acid secretion and reducing oxidative stress. D-chiro-Inositol improves insulin resistance, lowers hyperglycemia and circulating insulin levels, reduces serum androgen levels, and ameliorates some metabolic abnormalities associated with X syndrome by mimicking the action of insulin. Additionally, D-chiro-Inositol can induce a reduction in pro-inflammatory factors (such as Nf-κB) and cytokines (such as TNF-α), thereby exerting anti-inflammatory effects. D-chiro-Inositol may be used in the study of liver cirrhosis, breast cancer, type 2 diabetes, and polycystic ovary syndrome .

HY-N0755

Rhoifolin	Structural Classification Rhus succedanea Flavonoids Classification of Application Fields Flavones Plants Disease Research Fields Endocrinology Anacardiaceae Cancer	Insulin Receptor GLUT NF-κB p38 MAPK Autophagy
Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .

HY-B0239R

Chloramphenicol (Standard)	Structural Classification Source classification Antibacterial Disease Research Endogenous metabolite Other Antibiotics Human Gut Microbiota Metabolites Plant Cell Culture Microorganisms Antibiotics Resistance Selection Animal Husbandry Anticancer	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP
Chloramphenicol (Standard) is the analytical standard of Chloramphenicol. This product is intended for research and analytical applications. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .

HY-N0755R

Rhoifolin (Standard)	Structural Classification Rhus succedanea Flavonoids Flavones Plants Anacardiaceae	Insulin Receptor GLUT NF-κB p38 MAPK Autophagy
Rhoifolin (Standard) is the analytical standard of Rhoifolin. This product is intended for research and analytical applications. Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .

HY-113513

5-HEPE	Microorganisms Source classification	Others
5(S)-HEPE is an active metabolite of eicosapentaenoic acid. It is formed from EPA by 5-lipoxygenase (5-LO). 5(S)-HEPE is an agonist of G protein-coupled receptor 119 (GPR119). It increases cAMP accumulation in CHO-K1 cells expressing human GPR119 when used at a concentration of 10 μM. 5(S)-HEPE increases glucose-induced insulin secretion from MING6 insulinoma pancreatic islets and glucagon-like peptide 1 (GLP-1) secretion from HuTu 80 adenocarcinoma cells when used at a concentration of 10 μM. Serum levels of 5(S)-HEPE are elevated in patients with hyperlipidemia.

Cat. No.	Product Name	Chemical Structure

HY-B0239S2

Threo-Chloramphenicol-d6

Threo-Chloramphenicol-d₆ is the deuterium labeled Chloramphenicol[1]. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research[2][3][4].

Cat. No.	Product Name		Classification